WEST PHARMACEUTICAL SERVICES INC (WST) West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Instruments & Supplies
West Pharmaceutical Services, Inc. NYSE:WST Healthcare · Medical - Instruments & Supplies
Mkt Cap $27.6B
Div Yield 0.22%
AH Close $392.15 +0.00% vs close
AH Close $392.15 +0.00% vs close
Mkt Cap $27.6B
Div Yield 0.22%
All Press Release SEC Filings News
Press Release
West Declares Quarterly Dividend
West Pharmaceutical Services' board declared a Q4 dividend of $0.26 per share, an 18% increase from the prior $0.22, marking the company's 34th consecutive annual dividend increase.
The dividend is payable November 18, 2026 to shareholders of record on November 11, 2026.
The raise underscores continued confidence in cash generation, with FY2025 net sales of $3.07 billion.
• 6d ago AI analysis › Press Release
West to Host Third-Quarter 2026 Conference Call
West Pharmaceutical Services will release third-quarter 2026 financial results before market open on Thursday, October 29, 2026.
A conference call to discuss results and business expectations follows at 8:00 a.m. Eastern Time, with a live webcast and advance registration for questioners.
For context, West generated $3.07 billion in fiscal 2025 net sales and is an S&P 500 constituent.
• 17d ago AI analysis › Press Release
West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
West Pharmaceutical Services announced its participation in CPHI Worldwide in Milan, where it will showcase its SelfDose patient-controlled injector powered by the Synchrony S1 prefillable syringe system.
West will also deliver a technical presentation on CDMO partnerships in combination drug-device development and join a panel on large-volume drug delivery choices.
The release contains no new financial, regulatory, or contractual information beyond background facts such as FY2025 net sales of $3.07 billion.
• 20d ago AI analysis › Press Release
West to Participate in Upcoming Investor Conferences
West Pharmaceutical Services announced it will present at the Wells Fargo Annual Healthcare Conference on September 10 and the Morgan Stanley Annual Global Healthcare Conference on September 14.
Live webcasts of the presentations will be accessible via the Investors section of the company's website, with replays available for 90 days.
The company reported fiscal year 2025 net sales of $3.07 billion and is a member of the S&P 500 index.
• 1mo ago AI analysis › Press Release ● Major
West Reports Second-Quarter 2026 Results
West Pharmaceutical Services reported Q2 2026 net sales of $872.3 million, up 13.8% year-over-year, driven by 12.7% organic growth and strength in its High Value Product Components business.
Adjusted diluted EPS increased 28.8% to $2.37, exceeding expectations, leading the company to raise its full-year 2026 adjusted EPS guidance to a range of $8.85 to $9.05.
Additionally, the company repurchased 1.8 million shares for $454.3 million in the first half of the year and declared a quarterly dividend of $0.22 per share.
• 3mo ago AI analysis › Press Release
West Declares Quarterly Dividend
West Pharmaceutical Services declared a regular quarterly dividend of $0.22 per share on its common stock.
The dividend is payable on August 5, 2026 to shareholders of record on July 29, 2026.
In its fiscal year 2025, the company generated $3.07 billion in net sales.
• 3mo ago AI analysis › SEC Filing
WST: 8-K · material agreement
West Pharmaceutical Services entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements with Daikyo Seiko, Ltd., effective July 14, 2026.
The Company maintains a 49% ownership interest in Daikyo, and the new agreements feature a 10-year term with terms that are substantially similar to the prior agreements established in 2017.
Under the terms, West receives an exclusive license to Daikyo's know-how and patents outside of Japan and is appointed as the exclusive distributor of Daikyo products in all countries other than Japan.
SEC 8-K • 3mo ago AI analysis › Press Release
West to Host Second-Quarter 2026 Conference Call
West Pharmaceutical Services will release second-quarter 2026 financial results before the market opens on Thursday, July 23, 2026.
Management will host a conference call at 8:00 a.m. Eastern Time to discuss the results and business expectations.
A webcast and slide presentation will be available in the Investors section, with a replay accessible for approximately 90 days.
• 3mo ago AI analysis › Press Release
West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
West Pharmaceutical Services completed the sale and transfer of manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System and associated facilities.
The transaction closed on July 1, 2026, though the company did not disclose the financial terms or consideration received for the assets.
West will continue to develop and manufacture other versions of the SmartDose platform, including the 10mL adaptive technology system.
• 3mo ago AI analysis › Press Release
West Appoints Michel Lagarde to be President and Chief Executive Officer
West Pharmaceutical Services appointed Michel Lagarde as its new President and CEO, effective August 31, 2026, succeeding retiring CEO Eric M. Green.
Lagarde brings extensive experience from Thermo Fisher Scientific, where he served as Executive VP and COO, and previously led operations at Patheon and Philips.
The board also elected Robert F. Friel as the new Board Chair, ensuring a stable leadership transition for the S&P 500 injectable drug delivery leader.
• 4mo ago AI analysis › SEC Filing ⚠ 2
WST: 8-K/A · regulatory action
West Pharmaceutical Services filed an amendment to its 8-K regarding a material cybersecurity incident detected in May 2026. The company reports that core enterprise systems have been restored and critical manufacturing, receiving, and shipping processes have restarted at all global sites.
The company states it is now fully operational across its manufacturing, supply chain, and commercial sites. No unauthorized activity or access has been observed since May 5, 2026.
Management believes the incident has not had, and is not reasonably likely to have, a material impact on the company’s 2026 second-quarter and full-year financial guidance.
SEC 8-K/A • 5mo ago SEC Filing ● Major ⚠ 4
WST: 8-K · material agreement
On May 7, 2026, West Pharmaceutical Services, Inc. (the “Company”) announced a material cybersecurity attack. The attack, detected on May 4, 2026, resulted in the exfiltration of certain data and the encryption of some systems. The Company promptly activated its incident response protocols, including taking systems offline globally and notifying law enforcement.
The incident has caused temporary disruptions to the Company’s business operations globally. While core enterprise systems and critical processes for shipping, receiving, and manufacturing have been restored at some sites, the timeline for a complete restoration is still uncertain.
The Company has engaged Palo Alto Networks’ Unit 42 to support the investigation, containment, and recovery efforts. The Company is also working with customers to mitigate risk and minimize delays.
The material impact on the Company’s financial condition and results of operations has not been determined at the time of filing, but the proactive response and ongoing investigation suggest significant potential risks.
SEC 8-K • 5mo ago Press Release
West to Participate in Upcoming Investor Conferences
West Pharmaceutical Services announced participation in two upcoming investor conferences: the Bank of America Global Healthcare Conference and the William Blair Annual Growth Stock Conference.
The company is a global leader in injectable drug administration solutions, reporting $3.07 billion in net sales for fiscal year 2025.
Webcasts of the presentations will be available on the company's website, with replays accessible for 90 days after each event.
• 5mo ago AI analysis › Press Release
West Reports First-Quarter 2026 Results
prnewswire.com • 6mo ago 
